-
- Robert J Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B Bolger, Sam S Chang, Toni K Choueiri, Brian A Costello, Ithaar H Derweesh, Shilpa Gupta, Steven L Hancock, Jenny J Kim, Timothy M Kuzel, Elaine T Lam, Clayton Lau, Ellis G Levine, Daniel W Lin, M Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R Plimack, Edward N Rampersaud, Bruce G Redman, Charles J Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B Wilder, Mary Dwyer, Rashmi Kumar, and National comprehensive cancer network.
- From Memorial Sloan Kettering Cancer Center; The University of Texas MD Anderson Cancer Center; Huntsman Cancer Institute at the University of Utah; Dana-Farber/Brigham and Women's Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Alabama at Birmingham Comprehensive Cancer Center; Vanderbilt-Ingram Cancer Center; Mayo Clinic Cancer Center; UC San Diego Moores Cancer Center; Moffitt Cancer Center; Stanford Cancer Institute; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; University of Colorado Cancer Center; City of Hope Comprehensive Cancer Center; Roswell Park Cancer Institute;University of Washington/Seattle Cancer Care Alliance; Massachusetts General Hospital Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Fox Chase Cancer Center; Duke Cancer Institute; University of Michigan Comprehensive Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; and National Comprehensive Cancer Network.
- J Natl Compr Canc Netw. 2015 Feb 1; 13 (2): 151-9.
AbstractThe NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These NCCN Guidelines Insights highlight the recent updates/changes in these guidelines, and updates include axitinib as first-line treatment option for patients with clear cell renal carcinoma, new data to support pazopanib as subsequent therapy for patients with clear cell carcinoma after first-line treatment with another tyrosine kinase inhibitor, and guidelines for follow-up of patients with renal cell carcinoma.Copyright © 2015 by the National Comprehensive Cancer Network.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:
![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.